Csenge Advisory Group Makes New $1.11 Million Investment in Illumina, Inc. $ILMN

Csenge Advisory Group purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 6,326 shares of the life sciences company’s stock, valued at approximately $1,112,000.

Several other large investors have also bought and sold shares of ILMN. Empowered Funds LLC lifted its stake in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Illumina during the second quarter worth $621,000. CW Advisors LLC acquired a new stake in shares of Illumina during the second quarter worth $275,000. Marshall Wace LLP increased its holdings in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC increased its holdings in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Stifel Nicolaus raised their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Citigroup boosted their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a report on Monday, August 3rd. Finally, Barclays upped their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $188.40.

Illumina Stock Up 8.9%

Shares of Illumina stock opened at $205.00 on Thursday. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $207.00. The business has a 50-day moving average of $185.90 and a two-hundred day moving average of $151.49. The company has a market capitalization of $30.95 billion, a P/E ratio of 38.25, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 earnings per share. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Activity at Illumina

In other news, insider Scott M. Davies sold 615 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares of the company’s stock, valued at $4,067,600. This represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,415,351 shares of company stock valued at $255,966,311. Corporate insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.